The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study
Open accessAbstract
BACKGROUND: Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the incidence rates of psychotic disorder. METHODS: -tetrahydrocannabinol (THC) in the different types of cannabis available across the sites, we divided the types of cannabis used by participants into two categories: low potency (THC <10%) and high potency (THC ≥10%). Assuming causality, we calculated the population attributable fractions (PAFs) for the patterns of cannabis use associated with the highest odds of psychosis and the correlation between such patterns and the incidence rates for psychotic disorder across the study sites. FINDINGS: Between May 1, 2010, and April 1, 2015, we obtained data from 901 patients with first-episode psychosis across 11 sites and 1237 population controls from those same sites. Daily cannabis use was associated with increased odds of psychotic disorder compared with never users (adjusted odds ratio [OR] 3·2, 95% CI 2·2-4·1), increasing to nearly five-times increased odds for daily use of high-potency types of cannabis (4·8, 2·5-6·3). The PAFs calculated indicated that if high-potency cannabis were no longer available, 12·2% (95% CI 3·0-16·1) of cases of first-episode psychosis could be prevented across the 11 sites, rising to 30·3% (15·2-40·0) in London and 50·3% (27·4-66·0) in Amsterdam. The adjusted incident rates for psychotic disorder were positively correlated with the prevalence in controls across the 11 sites of use of high-potency cannabis (r = 0·7; p=0·0286) and daily use (r = 0·8; p=0·0109). INTERPRETATION: Differences in frequency of daily cannabis use and in use of high-potency cannabis contributed to the striking variation in the incidence of psychotic disorder across the 11 studied sites. Given the increasing availability of high-potency cannabis, this has important implications for public health. FUNDING SOURCE: Medical Research Council, the European Community's Seventh Framework Program grant, São Paulo Research Foundation, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King's College London and the NIHR BRC at University College London, Wellcome Trust.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Use less than once a week was not associated with a psychotic disorder risk (other than acute psychoses which can emerge even with first time consumption of high THC doses).”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The prevalence of daily cannabis use and high potency cannabis use was positively associated with the incidence of treated psychosis across study sites in Europe and Brazil.”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“A multinational study in Europe and Brazil [50] found that daily use of high potency cannabis increased the risk of psychosis fivefold compared to non-users while daily use of low potency cannabis doubled the risk.”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“A multinational study in Europe and Brazil [50] found that daily use of high potency cannabis increased the risk of psychosis fivefold compared to non-users while daily use of low potency cannabis doubled the risk.”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marshall, M., Lewis, S., Lockwood, A., Drake, R., Jones, P., & Croudace, T. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,593
Self-citationMcGuffin, P. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810320088015 · Cited by 1,483
McGrath, J., Saha, S., Welham, J., El Saadi, O., MacCauley, C., & Chant, D. (2004) · BMC Medicine · doi:10.1186/1741-7015-2-13 · Cited by 1,072
Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis
Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw003 · Cited by 899
Self-citationDi Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., Bianconi, F., Gardner-Sood, P., O'Connor, J., Russo, M., et al. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00117-5 · Cited by 588
Self-citationHigh-potency cannabis and the risk of psychosis
Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.064220 · Cited by 567
Self-citationAssociation Between Cannabis and Psychosis: Epidemiologic Evidence
Gage, S. H., Hickman, M., & Zammit, S. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.001 · Cited by 379
Evaluating the public health impacts of legalizing recreational cannabis use in the United States
Hall, W., & Lynskey, M. (2016) · Addiction · doi:10.1111/add.13428 · Cited by 357
Self-citationTreated Incidence of Psychotic Disorders in the Multinational EU-GEI Study
Jongsma, H. E., Gayer-Anderson, C., Lasalvia, A., Quattrone, D., Mulè, A., Szöke, A., Selten, J.-P., Turner, C., Arango, C., Tarricone, I., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3554 · Cited by 335
Self-citationMurray, R. M., Quigley, H., Quattrone, D., Englund, A., & Di Forti, M. (2016) · World Psychiatry · doi:10.1002/wps.20341 · Cited by 315
Self-citation
Cited by
Mental health in elite athletes: International Olympic Committee consensus statement (2019)
Reardon, C. L., Hainline, B., Aron, C. M., Baron, D., Baum, A. L., Bindra, A., Budgett, R., Campriani, N., Castaldelli-Maia, J. M., Currie, A., et al. (2019) · British Journal of Sports Medicine · doi:10.1136/bjsports-2019-100715 · Cited by 1,277
Jauhar, S., Johnstone, M., & McKenna, P. J. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01730-x · Cited by 996
Cannabis use and cannabis use disorder
Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00247-4 · Cited by 552
Review of the Endocannabinoid System
Lu, H.-C., & Mackie, K. (2021) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.07.016 · Cited by 491
Freeman, T. P., Craft, S., Wilson, J., Stylianou, S., ElSohly, M., Di Forti, M., & Lynskey, M. T. (2021) · Addiction · doi:10.1111/add.15253 · Cited by 337
Self-citation
Metadata
- Authors
- Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H., Rodriguez, V., Jongsma, H. E., Ferraro, L., La Cascia, C., La Barbera, D., Tarricone, I., Berardi, D., Szöke, A., Arango, C., Tortelli, A., Velthorst, E., Bernardo, M., Del-Ben, C. M., Menezes, P. R., Selten, J.-P., Jones, P. B., Kirkbride, J. B., Rutten, B. P., de Haan, L., Sham, P. C., van Os, J., Lewis, C. M., Lynskey, M., Morgan, C., Murray, R. M., Amoretti, S., Arrojo, M., Baudin, G., Beards, S., Bernardo, M., Bobes, J., Bonetto, C., Cabrera, B., Carracedo, A., Charpeaud, T., Costas, J., Cristofalo, D., Cuadrado, P., Díaz-Caneja, C. M., Ferchiou, A., Franke, N., Frijda, F., García Bernardo, E., Garcia-Portilla, P., González, E., Hubbard, K., Jamain, S., Jiménez-López, E., Leboyer, M., López Montoya, G., Lorente-Rovira, E., Marcelino Loureiro, C., Marrazzo, G., Martínez, C., Matteis, M., Messchaart, E., Moltó, M. D., Nacher, J., Olmeda, M. S., Parellada, M., González Peñas, J., Pignon, B., Rapado, M., Richard, J.-R., Rodríguez Solano, J. J., Roldán Díaz, L., Ruggeri, M., Sáiz, P. A., Sánchez, E., Sanjuán, J., Sartorio, C., Schürhoff, F., Seminerio, F., Shuhama, R., Sideli, L., Stilo, S. A., Termorshuizen, F., Tosato, S., Tronche, A.-M., van Dam, D., & van der Ven, E.
- Affiliations
- King's College London (GB)
- University of Bath (GB)
- University of Cambridge (GB)
- University of Palermo (IT)
- University of Bologna (IT)
- Hospital General Universitario Gregorio Marañón (ES)
- Amsterdam UMC Location University of Amsterdam (NL)
- Universidade de São Paulo (BR)
- University College London (GB)
- Maastricht University Medical Centre (NL)
- ORCID
- Quattrone, Diego
- Freeman, Tom P
- Tripoli, Giada
- Gayer-Anderson, Charlotte
- Quigley, Harriet
- Jongsma, Hannah E
- Ferraro, Laura
- Tarricone, Ilaria
- Berardi, Domenico
- Arango, Celso
- Tortelli, Andrea
- Velthorst, Eva
- Menezes, Paulo Rossi
- Selten, Jean-Paul
- Jones, Peter B
- Kirkbride, James B
- Rutten, Bart PF
- Sham, Pak C
- Lewis, Cathryn M
- Lynskey, Michael
- Morgan, Craig
- Murray, Robin M
- Arrojo, Manuel
- Baudin, Grégoire
- Beards, Stephanie
- Bobes, Julio
- Bonetto, Chiara
- Cabrera, Bibiana
- Charpeaud, Thomas
- Costas, Javier
- Cuadrado, Pedro
- Hubbard, Kathryn
- Jamain, Stéphane
- Leboyer, Marion
- Lorente-Rovira, Esther
- Marrazzo, Giovanna
- Matteis, Mario
- Parellada, Mara
- Pignon, Baptiste
- Richard, Jean-Romain
- Ruggeri, Mirella
- Sáiz, Pilar A.
- Sanjuán, Julio
- Sartorio, Crocettarachele
- Schürhoff, Franck
- Shuhama, Rosana
- Sideli, Lucia
- Termorshuizen, Fabian
- Tosato, Sarah
- Tronche, Anne-Marie
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 6
- Issue
- 5
- Pages
- 427-436
- ISSN
- 2215-0366 (ISSN-L)
- PMC
- PMC7646282
- OpenAlex
- W2922855419
- Cited by
- 875
- References
- 32
- Citations by year
- 2026: 92 · 2025: 92 · 2024: 105 · 2023: 126 · 2022: 144 · 2021: 122 · 2020: 121 · 2019: 72
- FWCI
- 71.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, cc-by-nc)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, cc-by)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- Wellcome Trust (101272/Z/12/Z)
- Seventh Framework Programme (HEALTH-F2-2009-241909)
- Medical Research Council
- National Institute for Health and Care Research
- King's College London
- South London and Maudsley NHS Foundation Trust
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2012/0417-0)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- cannabis use, psychosis, first-episode psychosis, incidence, high-potency cannabis, tetrahydrocannabinol, daily cannabis use, population attributable fraction, cannabis availability, psychosis prevention, Europe, London, Amsterdam
- MeSH terms
- Adult, Brazil, Marijuana Abuse, Europe, Female, Humans, Male, Middle Aged, Psychotic Disorders, Incidence, Odds Ratio, Case-Control Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. https://app.cochat.ai/papers/10.1016/s2215-0366(19)30048-3
- The paper
- Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H., Rodriguez, V., Jongsma, H. E., Ferraro, L., La Cascia, C., La Barbera, D., Tarricone, I., Berardi, D., Szöke, A., Arango, C., Tortelli, A., Velthorst, E., Bernardo, M., Del-Ben, C. M., . . . van der Ven, E. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(19)30048-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.